Proprotein convertase subtilisin/kexin type 9 inhibitors in peripheral artery disease: A review of efficacy, safety, and outcomes

Table 1 Efficacy of proprotein convertase subtilisin/kexin type 9 inhibitors in reducing low-density lipoprotein levels and cardiovascular events in peripheral artery disease patients

	Drug	LDL-C reduction	CV event reduction
FOURIER	Evolocumab	59% at 48 wka	15%; (HR: 0.85; 95%CI: 0.79 to 0.92a)
ODYSSEY	Alirocumab	55% at 4 mo; 63% at 48 mo	15% reduction in the composite of CHD death, MI, ischemic stroke, or unstable angina requiring hospitalization

^aP < 0.001. CHD: Coronary heart disease; CI: Confidence interval; CV: Cardiovascular; HR: Hazard ratio; LDL-C: Low-density lipoprotein cholesterol; MI: Myocardial infarction.